The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of a BRCA1 or BRCA2 Mutation
Open accessAbstract
BACKGROUND: Multiparity and the use of oral contraceptives reduce the risk of ovarian cancer, but their effects on this risk in women with a BRCA1 or BRCA2 mutation are unclear. METHODS: We conducted a population-based case-control study of ovarian cancer among Jewish women in Israel. Women were tested for the two founder mutations in BRCA1 and the one founder mutation in BRCA2 that are known to be common among Jews. We estimated the effects of parity and oral-contraceptive use on the risk of ovarian cancer in carriers and noncarriers in separate analyses that included all control women, who did not have ovarian cancer. RESULTS: Of 751 controls who underwent mutation analysis, 13 (1.7 percent) had a BRCA1 or BRCA2 mutation, whereas 244 of 840 women with ovarian cancer (29.0 percent) had a BRCA1 or BRCA2 mutation. Overall, each additional birth and each additional year of use of oral contraceptives were found to lower the risk of ovarian cancer, as expected. Additional births were protective in separate analyses of carriers and noncarriers, but oral-contraceptive use appeared to reduce the risk only in noncarriers; among carriers, the reduction in the odds of ovarian cancer was 12 percent per birth (95 percent confidence interval, 2.3 to 21 percent) and 0.2 percent per year of oral-contraceptive use (-4.9 to 5.0 percent). CONCLUSIONS: The risk of ovarian cancer among carriers of a BRCA1 or BRCA2 mutation decreases with each birth but not with increased duration of use of oral contraceptives. These data suggest that it is premature to use oral contraceptives for the chemoprevention of ovarian cancer in carriers of such mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
INCESSANT OVULATION—A FACTOR IN OVARIAN NEOPLASIA ?
Fathalla, M. F. (1971) · The Lancet · doi:10.1016/s0140-6736(71)92335-x · Cited by 1,119
Oral Contraceptives and the Risk of Hereditary Ovarian Cancer
Narod, S. A., Risch, H., Moslehi, R., Dørum, A., Neuhausen, S., Olsson, H., Provencher, D., Radice, P., Evans, G., Bishop, S., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808133390702 · Cited by 615
Determinants of Ovarian Cancer Risk. II. Inferences Regarding Pathogenesis 2
(1983) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/71.4.717 · Cited by 535
Piegorsch, W. W., Weinberg, C. R., & Taylor, J. A. (1994) · Statistics in Medicine · doi:10.1002/sim.4780130206 · Cited by 479
Estrogen Replacement Therapy and Ovarian Cancer Mortality in a Large Prospective Study of US Women
Rodriguez, C. (2001) · JAMA · doi:10.1001/jama.285.11.1460 · Cited by 424
Cancer Incidence in a Cohort of Infertile Woman
Modan, B., Ron, E., Lerner-Geva, L., Blumstein, T., Menczer, J., Rabinovici, J., Oelsner, G., Freedman, L., Mashiach, S., & Lunenfeld, B. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009397 · Cited by 361
Self-citationParity, age at first childbirth, and risk of ovarian cancer
Adami, H.-O., Lambe, M., Persson, I., Ekbom, A., Adami, H. O., Hsieh, C. C., Trichopoulos, D., Ekbom, A., Lambe, M., Leon, D., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90749-8 · Cited by 347
Risk factors for ovarian cancer: a case-control study
Booth, M., Beral, V, & Smith, P. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.320 · Cited by 297
PERSONAL AND ENVIRONMENTAL CHARACTERISTICS RELATED TO EPITHELIAL OVARIAN CANCER
WHITTEMORE, A. S., WU, M. L., PAFFENBARGER, R. S., SARLES, D. L., KAMPERT, J. B., GROSSER, S., JUNG, D. L., BALLON, S., & HENDRICKSON, M. (1988) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115077 · Cited by 279
Determinants of Ovarian Cancer Risk. I. Reproductive Experiences and Family History 23
(1983) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/71.4.711 · Cited by 256
Cited by
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,104
Collaborative Group on Epidemiological Studies of Ovarian Cancer (2008) · The Lancet · doi:10.1016/s0140-6736(08)60167-1 · Cited by 822
Hereditary Cancer Predisposition Syndromes
Garber, J. E., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.042 · Cited by 697
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
Pal, T., Permuth‐Wey, J., Betts, J. A., Krischer, J. P., Fiorica, J., Arango, H., LaPolla, J., Hoffman, M., Martino, M. A., Wakeley, K., et al. (2005) · Cancer · doi:10.1002/cncr.21536 · Cited by 691
Metadata
- Authors
- Modan, B., Hartge, P., Hirsh-Yechezkel, G., Chetrit, A., Lubin, F., Beller, U., Ben-Baruch, G., Fishman, A., Menczer, J., Struewing, J. P., Tucker, M. A., Ebbers, S. M., Friedman, E., Piura, B., & Wacholder, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-07-26
- Volume
- 345
- Issue
- 4
- Pages
- 235-240
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2028682388
- Cited by
- 385
- References
- 22
- FWCI
- 19.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of a BRCA1 or BRCA2 Mutation. https://app.cochat.ai/papers/10.1056/nejm200107263450401
- The paper
- Modan, B., Hartge, P., Hirsh-Yechezkel, G., Chetrit, A., Lubin, F., Beller, U., Ben-Baruch, G., Fishman, A., Menczer, J., Struewing, J. P., Tucker, M. A., Ebbers, S. M., Friedman, E., Piura, B., & Wacholder, S. (2001). Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of a BRCA1 or BRCA2 Mutation. New England Journal of Medicine. https://doi.org/10.1056/nejm200107263450401
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.